新華製藥(000756.SZ):可行權的股票期權數量為516.78萬份
格隆匯12月28日丨新華製藥(000756.SZ)發佈關於公司2018年A股股票期權激勵計劃第二個行權期行權條件成就的公吿,第二個行權期符合行權條件的激勵對象人數為178人,可行權的股票期權數量為516.78萬份,佔公司目前總股本的0.82%,行權價格為5.61元/份;第二個行權期可行權股票期權若全部行權,公司股份仍具備上市條件;此次股票期權行權採用集中行權模式。
此次行權事宜需在有關機構的手續辦理結束後方可行權,屆時將另行公吿,敬請投資者注意。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.